Table 3 Distribution of cellular subpopulations in three areas of the liver using different antibodies.
| No | CD20 | CD4 | CD8 | CD56 | CD57 | FasL | Bak | |
|---|---|---|---|---|---|---|---|---|
| A. Central areas of portal tracts | ||||||||
| PAH | 14 | 2 *(93%) | 3(79%) | 1 (64%) | 1 (100%) | 1 (100%) | 2 (79%) | 1 (57%) |
| 2 (36%) | 2 (43%) | |||||||
| AAH | 10 | 2 (100%) | 3 (80%) | 1 (80%) | 1 (100%) | 1 (100%) | 2 (90%) | 1 (60%) |
| 2 (20%) | 2 (40%) | |||||||
| HCV | 5 | 2 (80%) | 2 (100%) | 2 (100%) | 2 (60%) | 1 (80%) | 2 (80%) | 2 (80%) |
| 3 (40%) | ||||||||
| CL | 10 | 2 (100%) | 2 (80%) | 2 (70%) | 1 (90%) | 0 (90%) | 0 (60%) | 1 (70%) |
| 2 (50%) | 1 (20%) | |||||||
| B. Periportal areas | ||||||||
| PAH | 14 | 1* (86%) | 1 (79%) | 3 (100%) | 1 (100%) | 1 (100%) | 2 (79%) | 1 (57%) |
| 2 (43%) | ||||||||
| AAH | 10 | 1 (100%) | 1 (80%) | 3 (100%) | 1 (100%) | 1 (100%) | 2 (90%) | 1 (60%) |
| 2 (40%) | ||||||||
| HCV | 5 | 2 (80%) | 2 (100%) | 2 (100%) | 2 (60%) | 1 (80%) | 2 (80%) | 2 (80%) |
| 3 (40%) | ||||||||
| CL | 10 | 1 (100%) | 2 (80%) | 2 (70%) | 1 (90%) | 0 (90%) | 1 (80%) | 1 (70%) |
| C. Lobular areas | ||||||||
| PAH | 14 | 1*(86%) | 1 (100%) | 2 (64%) | 1 (100%) | 1 (100%) | 1 (86%) | 2 (93%) |
| 3 (36%) | ||||||||
| AAH | 10 | 1 (90%) | 1 (100%) | 2 (50%) | 1 (100%) | 1 (100%) | 1 (80%) | 2 (90%) |
| 3 (50%) | ||||||||
| HCV | 5 | 1 (80%) | 2 (100%) | 1 (80%) | 1 (100%) | 1 (80%) | 2 (80%) | 2 (80%) |
| CL | 10 | 1 (100%) | 2 (100%) | 0 (100%) | 1 (100%) | 0 (90%) | 0 (60%) | 1 (70%) |
| 1 (20%) | ||||||||
Percentages of stained cells were independently analysed in different areas of the liver. *Scores found in at least 70% of biopsies analysed. The percentages of biopsies with each score (*) are indicated between brackets for each marker. As described in Methods the score was assessed on a five point scale: 0, 0–5%; 1, 5–20%; 2, 20–50%; 3, 50–80%; 4, 80–100%.
No, total number of patients.